Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | POLQ | O75417 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PPIB | P23284 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | GABRE | P78334 | 1/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29472278 | 0.89 | POLQ (0.54) | KMT2AAOC3POLQMEN1CYP3A4 | |
| SCHEMBL8860046 | 0.86 | KMT2A (0.46) | KMT2AAOC3POLQMEN1GAA | |
| SCHEMBL21480115 | 0.85 | POLQ (0.49) | KMT2APOLQMEN1PPIBCYP3A4 | |
| SCHEMBL1760632 | 0.83 | KMT2A (0.58) | KMT2APOLQMEN1PPIBCYP3A4 | |
| SCHEMBL6659655 | 0.82 | KMT2A (0.53) | KMT2APOLQMEN1PPIBCYP3A4 | |
| SCHEMBL4107217 | 0.82 | ALDH1A1 (0.46) | KMT2AAOC3MEN1GAANPSR1 | |
| SCHEMBL5601309 | 0.81 | KMT2A (0.56) | KMT2APOLQMEN1CYP3A4CYP2C9 | |
| SCHEMBL9887 | 0.81 | KMT2A (0.56) | KMT2APOLQMEN1CYP3A4CYP2C9 | |
| SCHEMBL7830345 | 0.81 | KMT2A (0.56) | KMT2APOLQMEN1CYP3A4CYP2C9 | |
| SCHEMBL9153457 | 0.81 | RAB9A (0.42) | KMT2AAOC3POLQMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161633-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | claimed |
| EP-1633349-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050038099-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | claimed |
| WO-2004098590-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1283824-A1 | PREPARATION OF ENANTIOMERICALLY ENRICHED AMINE-FUNCTIONALIZED COMPOUNDS | DSM N.V. (NL) | 2003-02-19 | — | — | EP | claimed |
| WO-2001090048-A1 | PREPARATION OF ENANTIOMERICALLY ENRICHED AMINE-FUNCTIONALIZED COMPOUNDS | DSM N.V. (NL) | 2001-11-29 | — | — | WO | claimed |
| US-20240068878-A1 | Time and/or Temperature Sensitive Devices and Methods of Use Thereof | FRESHPOINT QUALITY ASSURANCE LTD. (IL) | 2024-02-29 | — | — | US | disclosed |
| WO-2020160134-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20170152213-A1 | AMINE-CONTAINING LIPIDOIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-06-01 | — | — | US | disclosed |
| EP-3079680-A2 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS | Angiogenex, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9464035-B2 | Salicylic acid derivatives useful as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464035-B2 | Salicylic acid derivatives useful as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464035-B2 | Salicylic acid derivatives useful as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-10-11 | — | — | US | disclosed |
| WO-2003010311-A2 | PROCESS FOR PREPARING VARIANT POLYNUCLEOTIDES | DSM IP ASSETS B.V. (NL) | 2003-02-06 | — | — | WO | disclosed |
| EP-0826673-B1 | ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-0871619-B1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMA (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002020530-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
| WO-2001090396-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ESTERS AND ALCOHOLS | DSM N.V. (NL) | 2001-11-29 | — | — | WO | disclosed |
| US-5972946-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0826673-A1 | ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038099-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | KMT2A 3940/4885AOC3 1311/4885POLQ 4763/4885 |
| US-20070161633-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, HRH2 | KMT2A 2943/4885AOC3 311/4885POLQ 3617/4885 |
| US-20170152213-A1 | AMINE-CONTAINING LIPIDOIDS AND USES THEREOF | ABCB4, PHOSPHO1, SGMS2 | KMT2A 267/4885AOC3 450/4885POLQ 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.